GenSpera Receives FDA Clearance to Initiate Phase II Clinical Trials in Prostate Cancer

Posted by Colleen Koski

August 2, 2012 at 3:01 PM

GenSpera, Inc. (GNSZ-OTC) is one step closer to initiating its planned Phase II human clinical trial of its lead compound, G-202, in prostate cancer patients. On Tuesday, July 31, 2012, GenSpera announced that the U.S. Food and Drug Administration (FDA) cleared its Phase II trial for initiation. The Company expects to commence patient enrollment once it receives approval by the Institutional Review Boards for its six trial sites in the U.S. and the UK. The study could include up to 40 prostate cancer patients who failed previous hormonal therapy. GenSpera expects prostate cancer patients to particularly benefit from G-202 due to the drug’s ability to target slow-growing cancer cells.

Read More

Topics: GenSpera, Prostate Cancer

Healthcare Conferences and News: Week of 1/9 to 1/13

Posted by Karen Goldfarb

January 13, 2012 at 11:20 AM

This has been a big week for healthcare and biotech.

Read More

Topics: Crystal Research Associates, NVIV, GenSpera, OneMedForum, MedPro, biotech, Advaxis, Peregrine, Neuralstem, Leslie Ziegler, Gunnar Weikert, PPHM, General Cannabis, SearchCore

Corporate Milestone Update for GenSpera (GNSZ)

Posted by Karen Goldfarb

January 10, 2012 at 11:21 AM

Earlier today, GenSpera presented at the Biotech Showcase™ 2012 in San Francisco, California. GenSpera also recently participated in the Wall Street Analyst Forum, where Dr. Craig Dionne discussed the latest achievements and future milestones for GNSZ (shown below).

Read More

Topics: GenSpera, Craig Dionne, Targeted Therapies

Content not found
Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Date

see all

Posts by Topic